We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Rectangle Image
News

Metamark Receives Medicare Coverage for ProMark

Rectangle Image
News

Metamark Receives Medicare Coverage for ProMark

Read time:
 

Metamark Genetics, Inc has announced that Palmetto GBA has issued final local coverage determination (LCD) for ProMark®, the first and only proteomic prognostic test for early-stage prostate cancer. The finalized ProMark LCD is effective October 10, 2016, and approves Medicare reimbursement coverage for eligible prostate cancer patients to help determine which patients can be conservatively managed rather than treated with definitive surgery or radiation therapy.

The LCD is posted to the Medicare Coverage Database on the Centers for Medicare & Medicaid Services (CMS) website. “This is a tremendous step for ProMark, opening the door for greater access to essential, decision-making information for prostate cancer patients and their physicians, and enabling more informed and personalized treatment decisions” said Jerry Williamson, president and chief executive officer.

“This LCD attests to the growing adoption of ProMark as an important tool in the enhanced care of patients with clinically localized prostate cancer, and strongly supports Metamark’s continued commitment to achieving improved outcomes through the availability of better information.” Approximately 200,000 men are diagnosed with prostate cancer each year in the United States, with about 60% of those diagnoses in men over the age of 65.1

ProMark is validated to predict cancer aggressiveness in patients with biopsy Gleason Scores of 3+3 and 3+4, providing a fully independent and individualized prediction that the cancer can be managed without aggressive treatment, or an indication that therapy may be appropriate. The LCD provides coverage to patients with NCCN Very low and Low-risk disease.

Advertisement